Source: National Institutes of Health; National Institute of Dental and Craniofacial Research (NIDCR)
Scope: The McDevitt group’s role for this joint program that spans five research groups is to develop new methods for measurement of saliva-based analytes using microfluidic devices.
Grant number: 1U01 DE017793-01
Scope: Building on the biomarker discoveries made for the heart attack test and the momentum gathered from the parent U-01 program, the clinical study tasked here aims to validate a multiplexed salivary biomarker panel for the screening of AMI in the emergency room setting.
Grant number: 3 U01 DE017793-05S1
Scope: The development of a minimally-invasive brush biopsy test for oral cancer diagnosis (no scalpel biopsy would be required) that when combined with a novel microchip can be performed in clinics or dentist’s offices with results that are available in a matter of minutes (within visit).
Grant number: 1 RC2 DE020785-01
Source: Cancer Prevention Research Institute of Texas
Scope: Through this novel program, efforts are directed toward the development of a platform that can be used to accelerate the release of new cancer diagnostic tests and screening devices in the state of Texas. Through the unique partnerships here assembled an infrastructure will be developed that serves to span the essential areas of biomarker discovery, biomarker validation and clinical implementation with the goal of achieving technological innovation, reduced health care costs and improved healthcare outcomes. These efforts are unique in scope in terms of their capacity to combine nano science and engineering, state-of-the-art imaging methods, microfluidics concepts for sample processing and multiplexed biomarker panel analysis for the development of integrated test ensembles suitable for screening and diagnostic testing for oral, prostate and ovarian cancers.
Source: United Kingdom’s Home Office Scientific Development Branch (HOSDB)
Scope: RoadsideBNC drug tests to be developed with this Home Office Scientific Development Branch (HOSDB) program promise to serve as important tools for police officers to prosecute drugged driving. The BNC roadside drug tests are projected to save time and simplify the enforcement procedure by avoiding the need to take the suspected drugged drives to a police station, or health care facility, for testing. Completion of the proposed work promises a more convenient, cost-effective and comprehensive drug screening approach that may be applied for roadside testing of drivers at the point of arrest (POA).
Source: Alliance for NanoHealth: Department of Defense
Scope: The McDevitt group’s role for this joint program that spans two research groups is to develop new methods for measurement of acute trauma biomarkers in urine samples.
Dates: 9/1/09 – 8/31/11
PI: John Holcombe
Source: Bill and Melinda Gates Foundation
Scope: This program served to expand upon the successful demonstration of the highly promising chip-based CD4 counting technology developed by the University of Texas at Austin and Harvard Medical School. With this accelerated effort, the already established and productive collaborative program between the Harvard Medical School Division of AIDS and the Chemistry/Biochemistry Department at the University of Texas at Austin was expanded to target the short-term development and deployment of important CD4 diagnostic instrumentation that is suitable for immediate use in resource-scarce settings.